SEATTLE, Oct. 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that two abstracts, including its late-breaking abstract for TRU-015 for rheumatoid arthritis (RA), have been accepted for presentation at the American College of Rheumatology (ACR) Annual Scientific Meeting. This meeting will be held in conjunction with the Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting Nov. 6-11, 2007, at Boston's Convention and Exhibition Center.
Thursday, Nov. 8, 2007
Poster 309: Safety and Pharmacodynamics of Repeat Administration of TRU- 015, a CD20-Directed SMIP(TM) Therapeutic, in Subjects with Rheumatoid Arthritis
Friday, Nov. 9, 2007
Poster L7: TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Dose Ranging Trial
Abstracts, including late-breaking, for the ACR Annual Scientific Meeting are now available online at http://www.rheumatology.org.
Trubion is a biopharmaceutical company creating a pipeline of product
candidates to treat autoimmune disease and cancer. The company's product
candidates are novel proteins known as single-chain polypeptides and are
designed using its SMIP custom drug assembly technology. In less than 24
months, the company designed, developed and submitted to the FDA an
Investigational New Drug (IND) application for its lead product candidate,
TRU-015, which has completed a Phase IIb clinical trial for the treatment
of rheumatoid arthritis. In December 2005, the company entered into a
collaboration agreement with Wyeth for th
Copyright©2007 PR Newswire.
All rights reserved